prostate cancer

prostate cancer

STRIDE: Phase 2 study of sipuleucel-T in metastatic castration-resistant prostate cancer

1d ago
SOURCE  

Description

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune response from STRIDE, a randomised, phase 2, open-label trial of sipuleucel-T with concurrent versus sequential enzalutamide administration in patients with metastatic castration-resistant prostate cancer.